ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines
Initial $80m Series B From October Increased To $200m
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.
